The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.